GHX goes into private-equity ownership with Thoma Bravo
Procurement-automation platform could grow beyond its hospital-products roots
Calling it "one of the most significant companies in healthcare today," Thoma Bravo, a San Francisco private-equity firm, has completed its acquisition of GHX, also known as Global Healthcare Exchange, for an undisclosed sum. GHX (Louisville, CO) has an unusual pedigree: it was founded in 2000 by five major medical-products companies, during the first wave of Internet activity around e-commerce. Its membership has grown to 20 corporate shareholders, including the Big Three wholesalers and many of the top pharma and device firms.
GHX functions as a collaborative clearinghouse between hospital or GPO buyers and med-surg and other suppliers. It digitizes and stores contract details and expedites order processing for both sides of a transaction. They company claims to have cut over $4 billion out of supply chain costs for healthcare providers in the past four years.
For the past couple years, GHX has also tried to build a critical mass among pharma manufacturers and their trading partners to become a central data pool for serialized track-and-trace data, now mandated (under a 10-year implementation schedule) by the Drug Quality and Security Act. This might be one of the potential growth areas for GHX where access to Thoma Bravo capital will enable the company "to make healthcare a more efficient and automated industry," as Bruce Johnson, GHX CEO, said in a statement.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
